torsemide (demadex) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Torasemide is a pyridine-sulfonylurea type loop diuretic mainly used for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Also for the treatment of hypertension alone or in combination with other antihypertensive agents. It is also used at low doses for the management of hypertension. It is marketed under the brand name Demadex. Torasemide inhibits the Na+/K+/2Cl--carrier system (via interference of the chloride binding site) in the lumen of the thick ascending portion of the loop of Henle, resulting in a decrease in reabsorption of sodium and chloride. This results in an increase in the rate of delivery of tubular fluid and electrolytes to the distal sites of hydrogen and potassium ion secretion, while plasma volume contraction increases aldosterone production. The increased delivery and high aldosterone levels promote sodium reabsorption at the distal tubules, and by increasing the delivery of sodium to the distal renal tubule, torasemide indirectly increases potassium excretion via the sodium-potassium exchange mechanism. Torasemide's effects in other segments of the nephron have not been demonstrated. Thus torasemide increases the urinary excretion of sodium, chloride, and water, but it does not significantly alter glomerular filtration rate, renal plasma flow, or acid-base balance. Torasemide's effects as a antihypertensive are due to its diuretic actions. By reducing extracellular and plasma fluid volume, blood pressure is reduced temporarily, and cardiac output also decreases.   NCATS

Chemistry

  • SMILES: CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC2=CC=CC(C)=C2
  • InChIKey: NGBFQHCMQULJNZ-UHFFFAOYSA-N
  • Mol. Mass: 348.42
  • ALogP: 2.53
  • ChEMBL Molecule:
    torsemide  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral, Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0769 - $0.5639
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-isopropyl-3-((4-(3-methylphenylamino)pyridine)-3-sulfonyl)urea | 1-isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea | ac4464 | ac-4464 | bm-02015 | demadex | luprac | n-(((1-methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide | toradiur | torasemida | torasemide | torasemidum | torem 10 | torem 2.5 | torem 5 | torsemide

Organizations (80)

Research & Development (62)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (18)

Approved Indications (4)


 

Heart Failure

Hypertension

Myocardial Infarction

Stroke

Experimental Indications - Clinical Trial Phases 1-4 (16)


 

Body Weight Changes (Phase 1)

Cardiovascular Diseases (Phase 4)

Diabetes Mellitus, Type 2 (Phase 1)

Drugs, Generic (Phase 1)

Food-Drug Interactions (Phase 1)

Healthy Volunteers (Phase 1)

Heart Failure ()

Hypertension (Phase 4)

Kidney Failure, Chronic (Phase 1)

Metabolism (Phase 1)

Pharmacology (Phase 1)

Pre-Eclampsia (Phase 2)

Renal Insufficiency, Chronic (Phase 4)

Sports Medicine (Phase 1)

Therapeutic Equivalency (Phase 1)

Tricuspid Valve Insufficiency (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 28
  • # of Trial Organizations: 62

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue